Powerful HIV-1 Treatment with Lopinavir and Ritonavir Capsules LPV/r 40+10mg
ProcurenetShort description
Lopinavir and Ritonavir Capsules (LPV/r 40+10mg) play a vital role in the management of HIV-1 infection. The robust encapsulated oral pellets can help manage this chronic condition in adults as well as children over 14 days old. Key features include:
- Contents: Each capsule contains Lopinavir (40mg) and Ritonavir (10mg)
- Usage: Easily administer this medication by sprinkling it on sweetened porridge and consuming without chewing. Remember to consume this at room temperature for best results
- Stability: This product stays stable in temperatures below 30u00b0C, enhancing its longevity
- Shelf Life: Optimum effectiveness is maintained for up to 2 years from manufacturing
For complete safety, users must adhere closely to instructions regarding dosage and administration. Visit regulatory sources for any updates.
-
Procurenet Team Tshim Sha Tsui
Hong Kong
3 years
Description
LPV/r 40+10mg: A Dynamic Confluence of Lopinavir and Ritonavir for Advanced HIV-1 Treatment
The LPV/r 40+10mg formulation represents a powerful synthesis of Lopinavir and Ritonavir, two agents with proven efficacy against HIV-1 infection. As a significant therapeutic milestone, these capsules have been engineered to sustain their therapeutic robustness in diverse thermal conditions, thus ensuring their value as a cornerstone of HIV-1 therapy.
Technical Features and Therapeutic Potential
- Ranked amongst the most potent Protease Inhibitors (PIs), a class celebrated for its robust viral inhibitory potential.
- Exhibits a heat-stable formulation, providing a steady therapeutic efficacy.
- An optimized blend of Lopinavir (40mg) and Ritonavir (10mg), encapsulated as high-quality oral pellets for ease of administration.
Unique Characteristics
- Characterized as a boosted protease inhibitor, with a proven efficacy against HIV-1 infection.
- Effective when implemented in an antiretroviral therapy regimen alongside a minimum of two other antiretroviral drugs.
- Maintains therapeutic integrity under storage temperatures below 30°C.
- Recommended for twice daily administration in pediatric patients, catering to unique metabolic requirements.
- Powell form, easily administered mixed with room-temperature porridge, offering a practical solution for the patient.
- Regulatory approved and recognized globally, featuring on the 'WHO Prequalification Programme' and 'US FDA approved and tentatively approved lists'.
- Usage guidelines aligned with regional, national and WHO HIV treatment procedures.
These LPV/r 40+10mg Capsules serve as an effective therapeutic tool in the fight against HIV. Aided by the united strengths of Lopinavir and Ritonavir, they promise a bolstered antiretroviral therapy when used in unison with two other antiretroviral substances. Proper storage and adherence to medication guides and regional healthcare protocols will maximize their effectiveness. With these capsules, you have a capable ally in your battle against HIV-1.
